Galenic development

Unither pharmaceuticals, a single-dose specialist

Specializing in contract manufacturing, Unither ensures that its innovative galenic forms remain competitive, practical and easy to use for the patients. The development of those galenic formulations for pharmaceutical use aims to improve the lives of patients and doctors. Unither focuses on the development and manufacture of quality single-dose drugs using Blow-Fill-Seal (BFS), Preservative-free multidose (PFMD) and liquid stick-packs technologies.

Ideal for active patients' lifestyles, unit doses are dosage forms that are both easy to carry and administer as treatment products, thus significantly improving not only dosage accuracy but also patient compliance and treatment experience.

The development of new galenic formulations and products is adapted to the active principle, the route of administration and patients' needs, while meeting the regulatory requirements. In fact, galenic innovation plays a major part in improving treatment compliance and formulation persistence through the release of clinical studies and new galenic pharmaceutical formulations and products. Unither's teams, and particularly Bordeaux Innovation & Development Center, have cutting-edge expertise to help patients and doctors to be active and achieve their projects.

Some recent studies indicate that the reduced treatment burdens attributed to new galenic formulations and products are associated with better treatment compliance and persistence. New galenic formulations and products can definitely improve health outcomes in routine clinical practices.